Mandate

Vinge has advised Magle Chemoswed Holding AB in connection with its listing on Nasdaq First North Growth Market

Vinge has provided capital markets and transaction advice in connection with Magle Chemoswed Holding AB’s listing on Nasdaq First North Growth Market.

The prospectus was published on 2 June 2020 and trading on Nasdaq First North Growth Market was commenced on 30 June 2020. The offer related to 25 per cent of the total number of existing shares and following full subscription the value of the offer amounted to SEK 50 million.

Magle Chemoswed is an international contract development and manufacturing company and also develops its own product portfolio based on the company’s technology platforms. The company owns its manufacturing and development facilities in Malmö and works in relation to the development and manufacture of pharmaceuticals and medical devices on a contract basis. On 31 March 2020, the company had 70 employees and in 2019, the net turnover amounted to approximately SEK 128 million.

Vinge’s team consisted primarily of Kristian Ford, Christian Lindhé, Martin Svanberg, Sophia Reutercrona, Niklas Törnell, Tilda Hall, Daniel Melander Björner and Johan Cederblad.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025